Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company developing and commercializing medicines, particularly in areas requiring specialized biological and molecular approaches. Its R&D capabilities include therapeutic antibodies and small molecules across oncology, immunology, hematology and additional specialty disease areas. Chugai is headquartered in Tokyo and its shares trade on the Tokyo Stock Exchange under 4519. The company is affiliated with the Roche group while remaining a separately listed issuer, so its securities should not be merged into Roche's record.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company developing and commercializing medicines, particularly in areas requiring specialized biological and molecular approaches. Its R&D capabilities include therapeutic antibodies and small molecules across oncology, immunology, hematology and additional specialty disease areas. Chugai is headquartered in Tokyo and its shares trade on the Tokyo Stock Exchange under 4519. The company is affiliated with the Roche group while remaining a separately listed issuer, so its securities should not be merged into Roche's record.
TSE: 4519
engineered antibodies · small molecules · biologics
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
AUBE00 is an oral pan-KRAS macrocyclic peptide from the SnipeTide platform; Phase 1 began in 2025.
Business, technology & evidence
LUNA18 was discontinued in 2025. The annual report states that human oral absorption was confirmed and development shifted to AUBE00. This is company-reported information, not publicly available quantitative clinical data.
As of 2026-09-30, the website also listed AQUA07, an oral macrocyclic allosteric ALK inhibitor. Its clinical stage was not confirmed in this review.
The July 24 company release confirms clinical entry; the Japanese registry identifies an oral Phase 1 study recruiting participants.
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company developing and commercializing medicines, particularly in areas requiring specialized biological and molecular approaches. Its R&D capabilities include therapeutic antibodies and small molecules across oncology, immunology, hematology and additional specialty disease areas. Chugai is headquartered in Tokyo and its shares trade on the Tokyo Stock Exchange under 4519. The company is affiliated with the Roche group while remaining a separately listed issuer, so its securities should not be merged into Roche's record.
SecuritiesTSE: 4519
Program / service
Target / indication
Representative stage
Evidence & scope
AUBE00
pan-KRAS（GDP） · Solid tumors
Phase 1
No results found in this review
LUNA18 / paluratide
pan-RAS · Solid tumors
已终止
Human absorption reported by the company; quantitative data not disclosed
AQUA07
Allosteric ALK · ALK-positive non-small cell lung cancer
Phase 1
No results found in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Chugai reported that AQUA07, its third macrocyclic peptide project, had entered the clinical stage, with Phase 1 dosing in ALK-positive non-small cell lung cancer expected shortly. Its pipeline identifies AQUA07 as an oral allosteric ALK inhibitor originating from SnipeTide. The milestone does not establish that human efficacy has already been demonstrated.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
COMPANY RESEARCH